PCML
CRSP icon

Pavaki Capital Management LLC’s CRISPR Therapeutics CRSP Stock Holding History

Pavaki Capital Management LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Hold
5,000
– – 0.1% 113
2026
Q1 		$238K Buy
+5,000
New +$264K 0.1% 117

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Pavaki Capital Management LLC's CRSP Position: Q2 2026 in Review

Pavaki Capital Management LLC held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 5,000 shares worth $273K. The position accounts for 0.1% of the portfolio, ranked #113.

Pavaki Capital Management LLC first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Pavaki Capital Management LLC held 5,000 shares of CRISPR Therapeutics worth $273K as of Q2 2026.
  • Pavaki Capital Management LLC left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.1% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #113 holding.
  • Pavaki Capital Management LLC first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.